Biopsy of breast cancer metastases: Patient characteristics and survival

Shlomit Strulov Shachar, Tanya Mashiach, Georgeta Fried, Karen Drumea, Noa Shafran, Hyman B. Muss, Gil Bar-Sela

Research output: Research - peer-reviewArticle

Abstract

Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010-2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Conclusions: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.

LanguageEnglish (US)
Article number7
JournalBMC Cancer
Volume17
Issue number1
DOIs
StatePublished - Jan 4 2017

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Biopsy
Survival
Hormones
human ERBB2 protein
Recurrence
Multivariate Analysis
Lung
Mortality
Liver
Brain
Neoplasms

Keywords

  • Biopsy
  • Breast carcinoma
  • Pathology
  • Recurrent-metastatic disease
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Shachar, S. S., Mashiach, T., Fried, G., Drumea, K., Shafran, N., Muss, H. B., & Bar-Sela, G. (2017). Biopsy of breast cancer metastases: Patient characteristics and survival. BMC Cancer, 17(1), [7]. DOI: 10.1186/s12885-016-3014-6

Biopsy of breast cancer metastases : Patient characteristics and survival. / Shachar, Shlomit Strulov; Mashiach, Tanya; Fried, Georgeta; Drumea, Karen; Shafran, Noa; Muss, Hyman B.; Bar-Sela, Gil.

In: BMC Cancer, Vol. 17, No. 1, 7, 04.01.2017.

Research output: Research - peer-reviewArticle

Shachar, SS, Mashiach, T, Fried, G, Drumea, K, Shafran, N, Muss, HB & Bar-Sela, G 2017, 'Biopsy of breast cancer metastases: Patient characteristics and survival' BMC Cancer, vol 17, no. 1, 7. DOI: 10.1186/s12885-016-3014-6
Shachar SS, Mashiach T, Fried G, Drumea K, Shafran N, Muss HB et al. Biopsy of breast cancer metastases: Patient characteristics and survival. BMC Cancer. 2017 Jan 4;17(1). 7. Available from, DOI: 10.1186/s12885-016-3014-6
Shachar, Shlomit Strulov ; Mashiach, Tanya ; Fried, Georgeta ; Drumea, Karen ; Shafran, Noa ; Muss, Hyman B. ; Bar-Sela, Gil. / Biopsy of breast cancer metastases : Patient characteristics and survival. In: BMC Cancer. 2017 ; Vol. 17, No. 1.
@article{f890c11cb4224f30963a2c9f0f99132d,
title = "Biopsy of breast cancer metastases: Patient characteristics and survival",
abstract = "Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010-2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Conclusions: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.",
keywords = "Biopsy, Breast carcinoma, Pathology, Recurrent-metastatic disease, Survival",
author = "Shachar, {Shlomit Strulov} and Tanya Mashiach and Georgeta Fried and Karen Drumea and Noa Shafran and Muss, {Hyman B.} and Gil Bar-Sela",
year = "2017",
month = "1",
doi = "10.1186/s12885-016-3014-6",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Biopsy of breast cancer metastases

T2 - BMC Cancer

AU - Shachar,Shlomit Strulov

AU - Mashiach,Tanya

AU - Fried,Georgeta

AU - Drumea,Karen

AU - Shafran,Noa

AU - Muss,Hyman B.

AU - Bar-Sela,Gil

PY - 2017/1/4

Y1 - 2017/1/4

N2 - Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010-2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Conclusions: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.

AB - Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results: Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010-2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Conclusions: Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.

KW - Biopsy

KW - Breast carcinoma

KW - Pathology

KW - Recurrent-metastatic disease

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85008193465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008193465&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-3014-6

DO - 10.1186/s12885-016-3014-6

M3 - Article

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 7

ER -